List of References
(Volumes 2 - 6)

Safety: (Vol. 2)

(R1) Acute oral toxicity of H 72 6146 A (Octopirox) in female SPF-Wistar rats, Study-No. 74.0229, Hoechst AG.

(R2) Acute oral toxicity of H 72 6146 A (Octopirox) in male and female beagle-dogs; Study No. /4.0205, Hoechst AG.

(R3) Acute dermal toxicity of Octopirox® in male and female Wistar rats; Study-No. 86.1448, Hoechst AG.

(R4) Octopirox® - Test for primary dermal irritation in the rabbit; Study-No. 86.1390, Hoechst AG.

(R5) Primary skin irritation of a preparation of 0.5 % Octopirox, 12.5 % Steinapol SBFA 30 (40 %), 0.11 % citric acid and 86.89 % water (pH 7.0) in rabbits (patch test); Report No. 79.0735, Hoechst AG.

(R6) Primary skin irritation of a preparation of 1 % Octopirox, 0.33 % citric acid, 75 % PEG 400 and 23.67 % water (pH 7.0) in rabbits (patch test); Report No. 79.0736, Hoechst AG.

(R7) Skin tolerance of a preparation of 1.0 % Octopirox (Op. E 001), 0.3 % citric acid and 98.7 % 1,2-propylene glycol (pH 7.0) in rabbits; Report-No. 79.0737, Hoechst AG.

(R8) Primary skin irritation of a preparation of 0.5 % Octopirox, 12.5 % Steinapol SBFA 30 (40 %), 0.11 % citric acid and 86.89 % water (pH 7.0) in New Zealand rabbits (patch test); Report-No. 79.0763, Hoechst AG.

(R9) Primary skin irritation of 1 % Octopirox, 0.33 % citric acid, 75 % PEG 400 and 23.67 % water (pH 7.0) in New Zealand rabbits (patch-test); Report-No. 79.0764, Hoechst AG.

(R 10) Skin tolerance of a preparation of 1 % Octopirox (Op. e 001), = 0.3 % citric acid and 98.7 % 1,2-propylene glycol (pH 7.0) in New Zealand rabbits; Report-No. 79.0765, Hoechst AG.

(R 11) Study of eye irritation of MA REF 0370 (Shampoo with 0.3 % Octopirox) in rabbits; Report-No. 77.1099, Hoechst AG.

(R 12) Study of eye irritation of MA REF 03701 (Shampoo without Octopirox) in rabbits; Report-No. 77.1126, Hoechst AG.

(R 13) Study of eye irritation of MA REF 0380 (Shampoo with 0.3 Octopirox) in rabbits; Report-No. 77.1092, Hoechst AG.
(R 14) Study of eye irritation of MA REF 03801 (Shampoo without Octopirox) in rabbits; Report-No. 77.1128, Hoechst AG.

(R 15) Study of eye irritation of HS REF 03790 (Shampoo with 0.5% Octopirox) in rabbits; Report-No. 77.1127, Hoechst AG.

(R 16) Study of eye irritation of HS REF 037901 (Shampoo without Octopirox) in rabbits; Report-No. 77.1129, Hoechst AG.

(R 17) Study of eye irritation of Octopirox in aqueous Isopropanol in rabbits; Report-No. 79.0026, Hoechst AG.

(R 18) Study of eye irritation of aqueous Isopropanol in rabbits; Report-No. 79.0027, Hoechst AG.

(R 19) Testing for sensitizing properties of the substance H 72 6146 A (Octopirox) in the guinea pig (by the method of E.V. Buehler); Report-No. 76.0027, Hoechst AG.


(R 21) Testing for sensitizing properties of the antidandruff substance H 72 6146 A (Octopirox) in humans; Report-No. 75.0881, Hoechst AG.

(R 22) Photocontact allergy test of Piroxtone Olamine; Tanaka, S.; Morioka, H.; Myamoto, M.; Sakaguchi, T.; Hoechst Japan Ltd., Department of Biological Science, June 1, 1983.

(R 23) Phototoxicity study with Octopirox in humans; H. Tronier, Hautklinik Dortmund, 8. September 1976.

(R 24) Oral range-finding study (30 days) of Octopirox in SPF-Wistar-rats; Report-No. 76.0450, Hoechst AG.

(R 25) A repeated-dose (30 days) oral toxicity study of Octopirox in beagle dogs; Report-No. 76.0400, Hoechst AG.

(R 26) Five weeks subcutaneous toxicity of Piroxtone Olamine in rats; Report of S. Toyoshima (Kejo Gijuku University, Department of Medical Science), H. Sato (Sasaki Research Institute), R. Sato, H. Sato and M. Motoyama (Japan Experimental Medical Research Institute Co., Ltd.), August 18, 1981.
Safety: (Vol. 3)

(R 27) Subacute dermal toxicity study in male and female rabbits with a hair-lotion and shampoo-preparation containing H 72 6146 A (Octopirox); Report-No. 76.0294, Hoechst AG.

(R 28) Repeated-dose (90 days) oral toxicity study of Octopirox in rats; Report-No. 77.0752, Hoechst AG.

(R 29) Repeated-dose (90 days) oral toxicity study of Octopirox in beagle dogs, Report-No. 77.0215, Hoechst AG.


Safety: (Vol. 4)

(R 32) Octopirox: Test for mutagenicity in bacteria strains in the absence and presence of a liver preparation, Report No. 77.0815, Hoechst AG.

(R 33) Mutagenicity test of Piroctone Olamine; O. Nahanishi, H. Morioha, M. Miyamato, Hoechst Japan Ltd., Department of Biological Science, April 27, 1982.

(R 34) Study of mutagenic potential of the compound Octopirox Charge W 020 in strains of Salmonella typhimurium (Ames-Test); Report-No. 82.0692, Hoechst AG.

(R 35) Study of mutagenic potential of the compound Octopirox OP. A 038 in strains of Salmonella typhimurium (Ames Test); Report No. 82.0693, Hoechst AG.

(R 36) An oral mutagenicity study (Micronucleus-test) with Octopirox in mice; Report-No. 77.0677, Hoechst AG.

(R 37) Micronucleus-test of Piroctone Olamine in mice; M. Harusaka, K. Nabeshima; Biological Science Laboratories, Lion Corporation, 1981.


(R 39) Lack of in vivo binding to DNA of Piroctone Olamine; P. Sagelsdorff, W.K. Lutz, Ch. Schlatter; Swiss Federal Institute of Technology and University of Zürich, Sept. 16, 1983.

(R 40) An oral embryotoxicity study with Octopirox in rabbits; Report-No. 79.0603, Hoechst AG.

(R 41) Teratological study of Piroctone Olamine in rats; S. Toyoshima (Keio University), R. Satch, M. Kashima, M. Takahashi (Japan Experimental Medical Research Institute), June 30, 1981.
(R 42) Teratological study of Piroctone Olamine in rats – Subcutaneously administration at different times during organogenesis; T. Kitatani, M. Akaike, K. Takayama, M. Miyamoto; Research and Development Laboratories, Hoechst Japan Ltd., April 19, 1982.

(R 43) Subcutaneous administration of Piroctone Olamine to rats from pre-conceptional period through early stage of gestation. R. Sato, M. Kajima, Nippon Experimental Medical Research Institute, March 22, 1983.

(R 44) Effects of Piroctone Olamine subcutaneously given during the last third of gestation and the period of lactation in the rat; R. Sato, M. Kajima, Nippon Experimental Medical Research Institute; March 22, 1983.

(R 45) Pharmacokinetic studies of Octopirox-14C after dermal, oral and intravenous administration to rats. Report-No. 01-L42-0325-80, Hoechst AG, November 27, 1980.


(R 47) Percutaneous absorption of Octopirox; W.E. Parish, Unilever Research, Environmental Safety Laboratory, August 1983.


(R 52) Patch test for investigating the skin-irritant effect of cosmetic products in humans; Tronnier, H., Institute for experimental dermatology, June 17, 1991

(R 53) Patch test for investigating the skin-irritant effect of cosmetic products in humans; Tronnier, H., Institute for experimental dermatology, June 17, 1991

(R 54) OECD Acute Inhalation Toxicity Evaluation of Octopirox; Study No. 191-1456, International Research and Development Corporation, 21.2.1990
Efficacy: (Vol. 5)

(E1) The aetiology of dandruff and the mode of action of the therapeutic agents.

(E2) Fast, noninvasive method for molecular detection and differentiation of Malassezia yeast species on human skin and application of the method to dandruff microbiology.


(E7) Report Hoechst AG, H 726146A, 05.01.1977.


(E11) Stability test of Octopirox® (piroctone olamine) substance for 3 years at room temperature, Dr. Futterer, Hoechst AG, 30.06.1981.

(E12) Stability test of Octopirox® shampoo (0.5 % w/w) for 3 years at room temperature, Dr. Futterer, Hoechst AG, 25.09.1981.


(E14) Radiometrische Untersuchungen zur Substanzität des Antischuppenwirkstoffs Piroctone Olamine an Humanhaar.


(E 19) Spectrophotometric determination of Octopirox in cosmetic compositions (e.g. Shampoo), Clariant GmbH, May 2000.

(E 20) Determination of Octopirox in Shampoos by IIPLC, Clariant GmbH, 02.03.2001.


(E 22) Piroctone Olamine shampoo vs. an inactive shampoo anti-dandruff activity using the half-head technique/Life Science Research, 24.04.1980.

(E 23) Piroctone Olamine shampoo vs. a competitor's shampoo, anti-dandruff activity using the half-head-technique. Life Science Research, 1981.

(E 24) Piroctone Olamine shampoo vs. 1 % DTPD/MgSO4 Shampoo, comparative trial of antidandruff efficacy using the half-head technique/Life Science Research Ltd, 27.06.1984.

**Efficacy:** (Vol. 6)


(E 27) Efficacy report: A double-blind placebo-controlled four-way parallel group trial to evaluate the efficacy of Octopirox 0.75 % compared to Zinc Pyrithione 1 % and Climbazole 0.75 % in the treatment of seborrhoeic dandruff on the scalp, Hoechst AG and Parcxl GmbH, 08.01.1997.

(E 28) Clinical Study to evaluate the anti-dandruff efficacy of Shampoos, proDerm Institute, study 99.110-11, 04.02.2000.


(E 33) Antidandruff Hair Tonic containing piroctone olamine, Dr. Eberhard Futterer, Cosmetics&Toiletries 103 (1988), 47-49.


(E 36) Synergistic behaviour between AHA and BHA's esters with MEA-Piroctone Olamine for antidandruff shampoo formulation, F. Montesion, C. Genova, G. Calloni, The world directory for the cosmetic industry 2000, pp. 54-56.


(E 38) Head&Shoulders-New Improved Head&Shoulders, Product Brochure, Procter&Gamble 2000.


(E 46) Certificate of Analysis Octopirox (H 72 6146 A), Hoechst AG, 16.01.1976.
(E 47) Product documentation Octopirox, 1976.